| Date | Title | Description |
| 06.06.2025 | Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair | Mr. Chin brings over 20 years of financial experience across public and private healthcare organizations
Mr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financing
Mr. Chin’s appointm... |
| 16.04.2025 | Biomerica Announces Reverse Stock Split | Shares Expected to Begin Trading on Split-Adjusted Basis on April 21, 2025
IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, today announced that... |
| 16.01.2025 | United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer | - 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer
- Prostate Cancer: The Second Most Common Cancer in Men Globally
IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomeri... |
| 16.01.2025 | United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer | - 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer
- Prostate Cancer: The Second Most Common Cancer in Men Globally
IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomeri... |
| 15.01.2025 | Biomerica Reports Second Quarter Fiscal 2025 Financial Results | - Total Revenue Increases 5% Year-Over-Year
- Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings
IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global... |
| 15.01.2025 | Biomerica Reports Second Quarter Fiscal 2025 Financial Results | - Total Revenue Increases 5% Year-Over-Year
- Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings
IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global... |
| 07.11.2024 | Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements | IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Ma... |
| 30.10.2024 | Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain | Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from www.infoodsIBS.com without needing to visit a doctor’s officeWith a simple, at-home finger-prick blood sample, patients can receive a pe... |
| 04.09.2024 | The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer | - 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer
- First order already shipped to Saudi Arabia
- Prostate Cancer is the Second Most Common Cancer in Men Globally
IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomeric... |
| 29.08.2024 | Biomerica Reports Fiscal 2024 Year End Results | Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger Growth
Significant Cost Savings Plan Implemented After Year End – Expected to Deliver Expense Reductions of $1.0 to $1.4 Million i... |
| 29.08.2024 | Biomerica Reports Fiscal 2024 Year End Results | Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger Growth
Significant Cost Savings Plan Implemented After Year End – Expected to Deliver Expense Reductions of $1.0 to $1.4 Million i... |
| 01.07.2024 | Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers | inFoods® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick methodology in the privacy of their home
inFoods® IBS test is the first of its kind to identify specific foods that can trigger an Irritable ... |
| 12.04.2024 | Biomerica Reports Third Quarter 2024 Financial Results | Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024
InFoods IBS Positive Clinical Data to be Presented at the Upcoming Digestive Disease Week (... |
| 10.11.2023 | Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16 | IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conferenc... |
| 14.04.2023 | Biomerica Reports Q3 Fiscal 2023 Results | For the nine months ended February 28, 2023 vs. the same period in 2022, revenues, excluding sales of Covid-related products, increased by 16%.
InFoods® IBS Laboratory Developed Test (LDT) validation testing at the CLIA Lab has been complet... |
| 14.04.2023 | Biomerica Reports Q3 Fiscal 2023 Results | For the nine months ended February 28, 2023 vs. the same period in 2022, revenues, excluding sales of Covid-related products, increased by 16%.
InFoods® IBS Laboratory Developed Test (LDT) validation testing at the CLIA Lab has been complet... |
| 07.03.2023 | Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock | IRVINE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. BMRA ("Biomerica"), a global provider of advanced medical products, announced today the closing of its previously announced underwritten public offering of an aggr... |
| 02.03.2023 | Biomerica Announces Proposed Underwritten Public Offering of Common Stock | /EIN News/ -- IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today that it has commenced an underwritten public offering of its comm... |
| 13.01.2023 | Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022 | InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting
Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including ... |
| 08.12.2022 | Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE | Expands Commercialization Efforts in Areas with High Unmet Needs
/EIN News/ -- IRVINE, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) received clearance from the Kingdom of Saudi Arabia Food and Dru... |
| 13.10.2022 | Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022 | Notice of Patent Allowance in Australia containing broad claims pertaining to treating ADD/ADHD using the InFoods® Technology Notice of Patent Allowance in Japan containing broad claims pertaining to treating Depression using the InFoods® T... |
| 13.10.2022 | Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022 | Notice of Patent Allowance in Australia containing broad claims pertaining to treating ADD/ADHD using the InFoods® Technology Notice of Patent Allowance in Japan containing broad claims pertaining to treating Depression using the InFoods® T... |
| 30.08.2022 | Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer | InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022
Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development Executive
IRVINE, Calif., Aug. 30, 2022 (GLO... |
| 29.08.2022 | Biomerica Reports Fiscal 2022 Year End Results | Revenues increase 162% for fiscal 2022 vs fiscal 2021
Revenues for fiscal Q4 2022 up 403% vs. fiscal Q4 2021
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced med... |
| 12.05.2022 | Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™ | - Attaining CE Mark is a major step toward commercialization –
- World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated H. pylori as a Class 1 ... |
| 26.04.2022 | Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population | Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection
H. pylori infection is also a major cause of peptic ulcers
IRVINE, Calif., Ap... |
| 13.01.2022 | Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021 | Revenues up 239% over prior year fiscal second quarter
Customer orders backlog of over $4.0 million at November 30, 2021
Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon Disease Test during fiscal second quarter
InFoo... |
| 16.12.2021 | Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million | InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022.
IRVINE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced... |
| 16.12.2021 | Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million | InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022.
IRVINE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced... |
| 16.12.2021 | Biomerica : Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to approximately $4.6 Million - Form 8-K | Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to approximately $4.6 Million
-InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, ... |
| 04.11.2021 | Biomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment | Studies show that 13-20% of Canadians suffer from IBS at any given time1.
The lifetime risk for a Canadian to develop IBS is 30%1.
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today announced that the Can... |
| 15.10.2021 | Biomerica Reports Results for Fiscal First Quarter ended August 31, 2021 | Revenues up 10% over fiscal first quarter 2021, and 20% over fiscal fourth quarter 2021
Customer orders backlog of over $1.5 million at August 31, 2021
Following close of first fiscal quarter 2022, Walmart began online sales of Biomerica’s ... |
| 28.08.2021 | Biomerica Reports Fiscal 2021 Year End Results | Revenues increase 7.6% for fiscal 2021 vs fiscal 2020.
InFoods® IBS Endpoint Trial expected to be fully enrolled in less than 2 weeks.
Biomerica receives multiple notices of allowance for patents covering the InFoods® Technology Platform pr... |
| 24.06.2021 | Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™ | Prevalence of H. pylori infection in the United States is approximately 35% to 40% of the population
IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has signed an exclusive five-year d... |
| 15.06.2021 | BIOMERICA, INC.
Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment | IBS is one of the most important gastrointestinal disorders in Mexico, with a prevalence of around 16% [1] (approximately 20 million patients)
Broadens InFoods® global patent coverage with recently allowed patents in Korea and Japan
IRVINE,... |
| 11.05.2021 | BIOMERICA, INC.
Biomerica's Fast 15-Minute Easy to Use COVID-19 Antigen Test Now Available With Simple Nasal Swab | Less invasive nasal swab taken from front opening of the nose is more comfortable for patients
Test can be performed by doctors, school and company nurses, and medical assistants, in any location without specialized equipment
IRVINE, Calif.... |
| 15.04.2021 | BIOMERICA, INC.
Biomerica Reports 208% Increase In Q3 Fiscal 2021 Sales, Over Q3 Fiscal 2020 | Sales increase driven by first sales of COVID-19 Antigen Rapid Test in Europe after January 2021 CE Mark approval
Awarded two new patents for InFoods® diagnostic guided therapy technology, including the first Japanese patent
InFoods® IBS di... |
| 06.09.2011 | The MassDevice Weekly Checkup: Sept. 6, 2011 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 29.08.2011 | The MassDevice Weekly Checkup: August 29, 2010 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 25.07.2011 | The MassDevice Weekly Checkup: July 25, 2011 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 27.06.2011 | The MassDevice Weekly Checkup: June 27, 2010 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 08.03.2011 | The MassDevice Weekly Checkup: March 8, 2011 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 22.02.2011 | The MassDevice Weekly Checkup: February 22, 2011 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 01.02.2011 | The MassDevice Weekly Checkup: February 1, 2011 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 18.01.2011 | The MassDevice Weekly Checkup: January 18, 2011 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 05.01.2011 | The MassDevice Weekly Checkup: January 5, 2011 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 31.08.2010 | The MassDevice Weekly Checkup: August 31, 2010 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 29.06.2010 | The MassDevice Weekly Checkup: June 29, 2010 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 15.06.2010 | The MassDevice Weekly Checkup: June 15, 2010 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 02.06.2010 | The MassDevice Weekly Checkup: June 1, 2010 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 10.03.2010 | The MassDevice Weekly Checkup: March 9, 2010 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 22.02.2010 | The MassDevice Weekly Checkup: February 23, 2010 | Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
The MassDevice Indices are weighted according to market capitalization, based on the number of s... |
| 29.12.2009 | Annual Checkup: The gainers and losers in medical device stocks this year | All year our Weekly Checkup calculated the biggest gainers and losers among publicly traded medical device companies, comparing Monday morning’s opening share prices with their value when the markets close each Friday afternoon. As 2009 dra... |
